| Literature DB >> 34027806 |
Wan Liao1, Yi Chen1, Zongping Zhu1, Jiao Chen1, Tianhui Gao1, Boonjai Limsila2, Yenchit Techadamrongsin2, Lei Wang3, Jiali Yu1, Chaomei Fu1, Rui Li1.
Abstract
CONTEXT: Processing with vinegar could enhance the efficacy and reduce the toxicity of Curcuma phaeocaulis Valeton. (Zingiberaceae), a Chinese herbal medicine with anti-inflammatory and antitumor activities.Entities:
Keywords: Ezhu; LC50 values; Volatile oil; cardiotoxicity; intersegmental blood vessels; ovarian coefficient; uterine coefficient
Mesh:
Substances:
Year: 2021 PMID: 34027806 PMCID: PMC8159270 DOI: 10.1080/13880209.2021.1874427
Source DB: PubMed Journal: Pharm Biol ISSN: 1388-0209 Impact factor: 3.503
Figure 1.The toxicity C. phaeocaulis before and after processing with vinegar in zebrafish.
Figure 2.Embryonic development of zebrafish at different time points. (A) Blank control group; (B) Volatile oil of C. phaeocaulis (100 µg/mL). (C) Volatile oil of C. phaeocaulis vinegar-processed products (100 µg/mL); (D) Water decoction of C. phaeocaulis (200 µg/mL); (E) Water decoction of C. phaeocaulis vinegar-processed products (200 µg/mL).
Figure 3.The effect of volatile oil of C. phaeocaulis and its vinegar-processed products on zebrafish heart morphology. (A) Blank control group. (B) Volatile oil of C. phaeocaulis (20 µg/mL). (C) Volatile oil of C. phaeocaulis (50 µg/mL). (D) Blank control group. (E) Volatile oil of C. phaeocaulis vinegar-processed products (20 µg/mL). (F) Volatile oil of C. phaeocaulis vinegar-processed products (50 µg/mL).
Figure 4.Vascular fluorescence of flk-GFP zebrafish strains. A. Blank control group; B. Volatile oil of C. phaeocaulis (20 µg/mL); C. Volatile oil of C. phaeocaulis vinegar-processed products (20 µg/mL). (A1-C1:×50, A2-C2:×100).
Changes in the body weights of rats (n = 8).
| Group | Dose (g/kg) | Original body weight | Day 1 | Day 4 | Day 7 | Day 10 | Day 13 | Day 16 |
|---|---|---|---|---|---|---|---|---|
| Control | 0 | 210.98 ± 1.59 | 222.21 ± 8.23 | 220.98 ± 14.30ΔΔ | 228.01 ± 12.33ΔΔ | 224.31 ± 14.29 | 231.86 ± 10.17 | 234.26 ± 14.49 |
| CR | 5.6 | 203.93 ± 3.99 | 205.54 ± 10.66**Δ | 217.83 ± 9.31ΔΔ | 222.23 ± 12.03ΔΔ | 209.03 ± 21.49 | 227.35 ± 19.25 | 231.01 ± 15.87 |
| CV | 5.6 | 207.03 ± 2.78 | 210.84 ± 11.43 | 214.43 ± 12.30Δ | 212.53 ± 7.33ΔΔ | 201.81 ± 7.53**Δ | 218.15 ± 8.02 | 228.33 ± 7.71Δ |
| Model | 0 | 210.45 ± 7.69 | 218.61 ± 13.72 | 199.70 ± 17.05** | 192.84 ± 22.54** | 220.23 ± 18.20 | 223.56 ± 15.35 | 231.60 ± 13.95 |
| MR | 5.6 | 204.67 ± 6.13 | 208.73 ± 14.76 | 216.73 ± 13.19Δ | 221.05 ± 10.41ΔΔ | 226.44 ± 16.02 | 210.82 ± 10.12** | 232.20 ± 8.83 |
| MV | 5.6 | 200.43 ± 2.37 | 202.44 ± 14.74**Δ | 213.39 ± 13.14Δ | 219.43 ± 14.22ΔΔ | 223.00 ± 16.65 | 226.41 ± 20.60 | 239.10 ± 16.45 |
| MD | 0.5 | 211.11 ± 5.82 | 224.86 ± 11.39 | 233.80 ± 13.77ΔΔ | 235.96 ± 12.15ΔΔ | 237.71 ± 11.65Δ | 242.28 ± 12.57Δ | 244.05 ± 16.21 |
*p < 0.05 and **p < 0.01 compared to the normal control group; Δp < 0.05 and ΔΔp < 0.01, compared to the model control group. Control + raw group (CR), control + vinegar group (CV), model group (blood stasis syndrome model), model + raw group (MR), model + vinegar group (MV), model + compound Danshen tablet group (positive drug control group, MD).
Changes in wet weights and coefficients of ovary and uterus in rats (n = 8).
| Group | Ovary wet weight (g) | Ovarian coefficient (%) | Uterus wet weight (g) | Uterine coefficient (%) |
|---|---|---|---|---|
| Control | 0.0098 ± 0.0035ΔΔ | 0.0514 ± 0.0021ΔΔ | 0.5979 ± 0.1690 | 0.2716 ± 0.0770 |
| Model | 0.0226 ± 0.0080** | 0.0643 ± 0.0113* | 0.6166 ± 0.2813 | 0.2836 ± 0.1284 |
| CR | 0.0193 ± 0.0068* | 0.0661 ± 0.0125* | 0.4829 ± 0.1574 | 0.2276 ± 0.0661 |
| CV | 0.0234 ± 0.0083* | 0.0695 ± 0.0089** | 0.4978 ± 0.2478 | 0.2334 ± 0.1157 |
| MR | 0.0159 ± 0.0056* | 0.0615 ± 0.0119 | 0.5479 ± 0.2068 | 0.2505 ± 0.0918 |
| MV | 0.0294 ± 0.0104 | 0.0649 ± 0.0079* | 0.5638 ± 0.2524 | 0.2570 ± 0.1217 |
| MD | 0.0414 ± 0.0146Δ | 0.0531 ± 0.0185ΔΔ | 0.6600 ± 0.2645 | 0.2891 ± 0.1333 |
Compared to the normal control group, *p < 0.05, **p < 0.01; compared to the model control group, Δp < 0.05, ΔΔp < 0.01. Control + raw group (CR), control + vinegar group (CV), model group (blood stasis syndrome model), model + raw group (MR), model + vinegar group (MV), model + compound Danshen tablet group (positive drug control group, MD).